Sacituzumab tirumotecan extends survival in previously treated endometrial cancer in phase 3 trial
Start here
The randomised, open-label phase 3 trial TroFuse-005/ENGOT-en23/GOG-3095, published in The Lancet on October 28, 2026, tested sacituzumab tirumotecan against treatment of physician's choice in patients with advanced or recurrent endometrial cancer who had already received platinum-based chemotherapy and immunotherapy. The antibody-drug conjugate met its goals, extending both progression-free survival and overall survival compared with physician's choice. The results position sacituzumab tirumotecan as a potential new option in a heavily pretreated setting where standard choices after platinum and immunotherapy are limited. Questions that remain open in the published coverage include how the benefit varies across biomarker-defined subgroups and what the full safety profile means for clinical adoption.
Written by a model from the reports · updated 8 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- LancetPickSacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
In a phase 3 trial in advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and immunotherapy, sacituzumab tirumotecan extended both progression-free survival and overall survival versus treatment of physician's choice.
Heat trend for this story
Heat now 15·Peak in the comparable set 17 (Oct 28 12:00)·Change over 24h in the comparable set –·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.